Therapeutic Effect Evaluation of Trimetazidine in Treatment of Heart Failure of Ischemic Cardiomyopathy

Objective To analyze the clinical therapeutic effect of trimetazidine in reatment of heart failure of ischemic cardiomyopathy.Methods 72 patients with ischemic cardiomyopathy were randomly divided into treatment group and control group,36 cases in each group.The control group received conventional anti-heart failure therapy,the treatment group received trimetazidine 30 mg ovally,3 times each day,based on conventional anti-heart failure therapy,the course of treatment was 3months.We examined left ventricular end systolic diameter(ESD),left ventricular enddiastolic diameter(EDD),left ventricular end systolic volume(ESV),left ventricular enddiastolic volume(EDV),fractional shortening(FS),stroke volume(SV),left ventricular eject fraction(LVEF)and 6-minute walking distance of two groups before and after treatment.Results The treatment of two groups were both effective on heart failure of ischemic cardiomyopathy.There were significant differences of ESV,FS,SV and LVEF in both groups before and after treatment(P0.05).ESD,ESV,FS,SV and LVEF in treatment group were significantly better than in control group 3 months after treatment(P0.05).No drug-related adverse reactions were found in both groups.Conclusion Trimetazidine can effectively improve heart function of patients with ischemic cardiomyopathy,and is worthy of clinical application.